What is MaxisIT?
MaxisIT® specializes in providing advanced software solutions for the pharmaceutical and life sciences industries, focusing on eClinical Integration and Adaptive Decision Support. Its flagship product, CT Renaissance®, is a clinical enterprise suite designed to integrate and orchestrate end-to-end functionalities within a uniform or hybrid plug-and-play architecture. This approach ensures interoperability, reusability, and scalability, enabling clients to achieve real-time harmonization. MaxisIT's solutions are geared towards helping pharmaceutical companies realize their vision of a safe, effective, and FDA-approved drug delivery at the lowest cost and fastest time to market. The company emphasizes strategic, enterprise-wide reusable and scalable solutions, supported by a world-class services team.
How much funding has MaxisIT raised?
MaxisIT has raised a total of $2.5M across 2 funding rounds:
Debt
$1M
Debt
$1.5M
Debt (2020): $1M with participation from PPP
Debt (2021): $1.5M led by PPP
What's next for MaxisIT?
The recent major strategic investment in MaxisIT signals a strong confidence in its technology and market position within the highly regulated pharmaceutical and life sciences sectors. Given the enterprise-level funding context, MaxisIT is likely poised for significant expansion, potentially focusing on enhancing its CT Renaissance® platform's capabilities, broadening its market reach, and deepening its partnerships with major pharmaceutical clients. This strategic capital infusion is expected to fuel further innovation in adaptive decision support and eClinical integration, reinforcing MaxisIT's commitment to accelerating drug development timelines and reducing costs for its customers.
See full MaxisIT company page
